NEW YORK (AP) -- Biotech company ImClone Systems Inc. said late Sunday it expects to disclose results of a Phase III study of a metastatic colorectal cancer treatment before the end of the week, so it is withdrawing from a previously scheduled investment conference. The company was scheduled to present at the JPMorgan Healthcare Conference.
